Lilly's oral GLP-1 pill orforglipron delivers 12.4% weight loss in ATTAIN-1 (NEJM)

Eli Lilly's orforglipron - a once-daily, small-molecule oral GLP-1 receptor agonist (no injection, no peptide backbone) - met its primary endpoint in the phase 3 ATTAIN-1 obesity trial, with the 36 mg dose producing 12.4% mean weight loss (~27 lb) at 72 weeks in 3,127 adults. Nearly 60% of participants on that dose lost at least 10% of body weight and ~40% lost at least 15%, with cardiometabolic improvements, results published in the New England Journal of Medicine. A parallel type-2-diabetes trial (ATTAIN-2, Lancet) confirmed statistically superior weight reduction versus placebo. While the magnitude trails injectable leaders tirzepatide and retatrutide, orforglipron is the first oral GLP-1 with phase 3 efficacy approaching the injectable class.